TY - JOUR KW - cardiovascular KW - chronic kidney disease KW - diabetes KW - heart failure KW - hyperkalaemia KW - hypertension KW - Mortality KW - potassium KW - variability AU - G. James AU - J. Kim AU - C. Mellström AU - K. Ford AU - N. Jenkins AU - C. Tsang AU - M. Evans AU - P. McEwan AD - Biopharmaceuticals Business Unit, AstraZeneca, Cambridge, UK. Biopharmaceuticals Business Unit, AstraZeneca, Gaithersburg, MD, USA. Biopharmaceuticals Business Unit, AstraZeneca, Gothenburg, Sweden. Health Economics and Outcomes Research Ltd, Cardiff, UK. Department of Diabetes and Endocrinology, University Hospital Llandough, Cardiff, UK. AN - 35371436 BT - Clin Kidney J C2 - PMC8967671 DO - 10.1093/ckj/sfab225 DP - NLM ET - 2022/04/05 LA - eng M1 - 4 N1 - 2048-8513 James, Glen Kim, Jennifer Mellström, Carl Ford, Kerrie L Jenkins, Nia C Tsang, Carmen Evans, Marc McEwan, Phil Orcid: 0000-0003-3540-8252 Journal Article Clin Kidney J. 2021 Nov 23;15(4):758-770. doi: 10.1093/ckj/sfab225. eCollection 2022 Apr. PY - 2022 SN - 2048-8505 (Print) 2048-8505 SP - 758 EP - 770 T2 - Clin Kidney J TI - Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study VL - 15 ER -